{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:32:36Z","timestamp":1782761556246,"version":"3.54.5"},"reference-count":58,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Mental disorders are observed in neuromuscular diseases, especially now that patients are living longer. Psychiatric symptoms may be severe and psychopharmacological treatments may be required. However, very little is known about pharmacotherapy in these conditions. We aimed to summarize the current knowledge on the use of psychopharmacological treatments for mental disorders in patients living with a neuromuscular disease. A scoping review was performed using the methodology of the Joanna Briggs Institute. Four databases were searched from January 2000 to July 2021. Articles were screened based on titles and abstracts. Full-text papers published in peer-reviewed journals in English were selected. Twenty-six articles met eligibility criteria, all being case reports\/series focusing on the psychopharmacological control of psychiatric symptoms for the following conditions: myasthenia gravis (n = 11), Duchenne (n = 5) and Becker (n = 3) muscular dystrophy, mitochondrial disorders (n = 3), glycogen storage disease (n = 1), myotonic dystrophy (n = 1), hyperkalemic periodic paralysis (n = 1), and congenital myasthenic syndrome (n = 1). None of the articles provided details on the decision-making process to choose a specific drug\/regimen or on follow-up strategies to monitor safety and efficacy. Larger studies showing real-world data would be required to guide consensus-based recommendations, thus improving current standards of care and, ultimately, the quality of life of patients and their families.<\/jats:p>","DOI":"10.3390\/brainsci12020176","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T01:41:59Z","timestamp":1643420519000},"page":"176","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Psychopharmacological Treatments for Mental Disorders in Patients with Neuromuscular Diseases: A Scoping Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3464-2848","authenticated-orcid":false,"given":"Chiara","family":"Brusa","sequence":"first","affiliation":[{"name":"Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy"},{"name":"Neuromuscular Unit, Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Gadaleta","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"D\u2019Alessandro","sequence":"additional","affiliation":[{"name":"Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Urbano","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Vacchetti","sequence":"additional","affiliation":[{"name":"Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-8419","authenticated-orcid":false,"given":"Chiara","family":"Davico","sequence":"additional","affiliation":[{"name":"Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-7383","authenticated-orcid":false,"given":"Benedetto","family":"Vitiello","sequence":"additional","affiliation":[{"name":"Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica S.","family":"Ricci","sequence":"additional","affiliation":[{"name":"Section of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana E.","family":"Mongini","sequence":"additional","affiliation":[{"name":"Neuromuscular Unit, Department of Neurosciences \u201cRita Levi Montalcini\u201d, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature","volume":"2","author":"Deenen","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.nmd.2020.11.009","article-title":"The 2021 version of the gene table of neuromuscular disorders (nuclear genome)","volume":"30","author":"Benarroch","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: Respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: Primary care, emergency management, psychosocial care, and transitions of care across the lifespan","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_8","first-page":"CD011539","article-title":"Enzyme replacement therapy for infantile-onset Pompe disease","volume":"2017","author":"Chen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls","volume":"385","author":"Darras","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.nmd.2020.02.019","article-title":"Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019","volume":"30","author":"Mercuri","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.nmd.2019.10.001","article-title":"A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy","volume":"29","author":"Messina","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.nmd.2021.06.001","article-title":"Health related quality of life in young, steroid-na\u00efve boys with Duchenne muscular dystrophy","volume":"31","author":"Campbell","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2438","DOI":"10.1212\/WNL.0000000000011896","article-title":"Development of a New Quality of Life Measure for Duchenne Muscular Dystrophy Using Mixed Methods","volume":"96","author":"Powell","year":"2021","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CND.0b013e3181c5053b","article-title":"The PedsQLTM in Pediatric Patients with Duchenne Muscular Dystrophy: Feasibility, Reliability, and Validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales","volume":"11","author":"Davis","year":"2010","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.nmd.2009.09.009","article-title":"The PedsQLTM in Pediatric Patients with Spinal Muscular Atrophy: Feasibility, Reliability, and Validity of the Pediatric Quality of Life InventoryTM Generic Core Scales and Neuromuscular Module","volume":"19","author":"Iannaccone","year":"2009","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/08830738050200100201","article-title":"Association of Duchenne Muscular Dystrophy with Autism Spectrum Disorder","volume":"20","author":"Wu","year":"2005","journal-title":"J. Child. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev. Med. Child. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Thangarajh, M., Spurney, C.F., Gordish-Dressman, H., Clemens, P.R., Hoffman, E.P., McDonald, C.M., Henricson, E.K., and CINRG Investigators (2018). Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS). PLoS Curr., 10.","DOI":"10.1371\/currents.md.4cdeb6970e54034db2bc3dfa54b4d987"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1212\/CPJ.0000000000000646","article-title":"Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1","volume":"9","author":"Johnson","year":"2019","journal-title":"Neurol. Clin. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/CPJ.0000000000000531","article-title":"Consensus-based care recommendations for adults with myotonic dystrophy type 1","volume":"8","author":"Ashizawa","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"ref_23","first-page":"e9184","article-title":"A Review of Psychiatric Comorbidity in Myasthenia Gravis","volume":"12","author":"Law","year":"2020","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1176\/appi.neuropsych.11110345","article-title":"The Psychiatric Presentation of Mitochondrial Disorders in Adults","volume":"24","author":"Anglin","year":"2012","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Aromataris, E., and Munn, Z. (2020). Chapter 11: Scoping Reviews (2020 Version). JBI Manual for Evidence Synthesis, JBI. Available online: https:\/\/synthesismanual.jbi.global.","DOI":"10.46658\/JBIRM-17-01"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.sleep.2020.08.008","article-title":"Myasthenic crisis due to anxiety and insomnia during COVID-19 pandemic","volume":"75","author":"Kalita","year":"2020","journal-title":"Sleep Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1176\/appi.neuropsych.18120383","article-title":"Management of Insomnia and Anxiety in Myasthenia Gravis","volume":"31","author":"Jordan","year":"2019","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ncn3.12267","article-title":"Clinical characteristics of patients with myasthenia gravis accompanied by psychiatric disorders","volume":"7","author":"Yamamoto","year":"2019","journal-title":"Neurol. Clin. Neurosci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16l02050","DOI":"10.4088\/PCC.16l02050","article-title":"Safe Use of Atypical Antipsychotics in a Patient with Postpartum Psychosis and a History of Seronegative Myasthenia Gravis","volume":"19","author":"Kyllo","year":"2017","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/JCP.0000000000000741","article-title":"Worsening of Myasthenia Gravis After Administration of Antipsychotics for Treatment of Schizophrenia: A Case Report and Review of Literature","volume":"37","author":"She","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.nmd.2016.02.006","article-title":"Worsening of myasthenia gravis after administration of injectable long-acting risperidone for treatment of schizophrenia; first case report and a call for caution","volume":"26","author":"Ismail","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4306\/pi.2013.10.3.300","article-title":"Myasthenia Gravis, Schizophrenia, and Colorectal Cancer in A Patient: Long-Term Follow-Up with Medication Complexity","volume":"10","author":"Kim","year":"2013","journal-title":"Psychiatry Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/pnp.264","article-title":"Myasthenia gravis unmasked by antipsychotic medication","volume":"17","author":"Wilson","year":"2013","journal-title":"Prog. Neurol. Psychiatry."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1176\/jnp.23.2.jnpe36","article-title":"Myasthenic Crisis May Mimic Antipsychotic-Induced Extrapyramidal Syndromes","volume":"23","author":"Chiu","year":"2011","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1176\/jnp.2006.18.3.427","article-title":"Myasthenia Gravis Disclosed by Lithium Carbonate","volume":"18","author":"Alevizos","year":"2006","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116-a","DOI":"10.1176\/jnp.13.1.116-a","article-title":"A Case of Myasthenia Gravis Preceded by Major Depression","volume":"13","author":"Shinkai","year":"2001","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Noda, S., Murakami, A., Kimura, S., Minamiyama, M., Katsuno, M., and Kuru, S. (2021, September 24). Duchenne Muscular Dystrophy Successfully Treated with Aripiprazole in a Patient with Autism Spectrum Disorder Symptoms Including Irritability. Intern. Med. Available online: https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7248-21\/_article.","DOI":"10.2169\/internalmedicine.7248-21"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mus.26803","article-title":"Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy","volume":"61","author":"Darmahkasih","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejpn.2018.09.005","article-title":"Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder","volume":"23","author":"Lionarons","year":"2019","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0883073818774439","article-title":"Descriptive phenotype of obsessive compulsive symptoms in males with Duchenne Muscular Dystrophy","volume":"33","author":"Lee","year":"2018","journal-title":"J. Child. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.nmd.2016.08.003","article-title":"Diagnosis and treatment of obsessive compulsive behavior in a boy with Duchenne muscular dystrophy and autism spectrum disorder: A case report","volume":"26","author":"Hendriksen","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/mus.26750","article-title":"Neurodevelopmental, behavioral, and emotional symptoms in Becker muscular dystrophy","volume":"61","author":"Lambert","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1590\/1516-4446-2018-0350","article-title":"First psychotic episode in an adult with Becker muscular dystrophy","volume":"41","author":"Santos","year":"2019","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1176\/appi.psy.48.2.167","article-title":"Treatment of Psychiatric Comorbidities in a Patient with Becker Muscular Dystrophy. ProQuest","volume":"48","author":"Chaichana","year":"2007","journal-title":"Psychosomatics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/WNF.0000000000000277","article-title":"Treatment of Depression with Duloxetine in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes","volume":"41","author":"Cozart","year":"2018","journal-title":"Clin. Neuropharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1440-1819.2006.01599.x","article-title":"Mania as a first presentation in mitochondrial myopathy","volume":"60","author":"Grover","year":"2006","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1176\/appi.psy.49.6.540","article-title":"Obsessive-compulsive disorder with mitochondrial disease","volume":"49","author":"Lacey","year":"2008","journal-title":"Psychosomatics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e222307","DOI":"10.1136\/bcr-2017-222307","article-title":"Acute psychosis in glycogen storage disease: A rare but severe complication","volume":"12","author":"Dunne","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0960-8966(01)00238-3","article-title":"Intolerance to neuroleptics and susceptibility for malignant hyperthermia in a patient with proximal myotonic myopathy (PROMM) and schizophrenia","volume":"12","author":"Schneider","year":"2002","journal-title":"Neuromuscul. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1176\/appi.neuropsych.11010025","article-title":"Bipolar Disorder Co-Occurring with Periodic Paralysis: A Case Report","volume":"24","author":"Raveendranathan","year":"2012","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.25244","article-title":"Rapsyn congenital myasthenic syndrome worsened by fluoxetine","volume":"55","author":"Visser","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/00023210-200721060-00004","article-title":"Mood and Anxiety Disorders in Patients with Myasthenia Gravis: Aetiology, Diagnosis and Treatment","volume":"21","author":"Kulaksizoglu","year":"2007","journal-title":"CNS Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jad.2019.03.036","article-title":"Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis","volume":"250","author":"Okkersen","year":"2019","journal-title":"J. Affect. Disord."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4088\/JCP.11r07237","article-title":"The psychiatric manifestations of mitochondrial disorders: A case and review of the literature","volume":"73","author":"Anglin","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.nmd.2015.05.005","article-title":"Care for a Novel Group of Patients\u2014Adults with Duchenne Muscular Dystrophy. In Proceedings of the 206th ENMC International Workshop, Naarden, The Netherlands, 23\u201325 May 2014","volume":"25","author":"Rahbek","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JND-200609","article-title":"Adult North Star Network (ANSN): Consensus Guideline for the Standard of Care of Adults with Duchenne Muscular Dystrophy","volume":"8","author":"Quinlivan","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/jimd.12196","article-title":"Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus","volume":"43","author":"Brown","year":"2020","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/2\/176\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:10:08Z","timestamp":1760134208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/12\/2\/176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["brainsci12020176"],"URL":"https:\/\/doi.org\/10.3390\/brainsci12020176","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]}}}